Clinical impact of an angiotensin I-converting enzyme insertion/deletion and kinin B2 receptor +9/-9 polymorphisms in the prognosis of renal transplantation

Biological Chemistry

Volumn 394, Issue 3, 2013, Pages 369-377

  Amorim, Carlos E N ^a   Nogueira, Eliana ^a   Almeida, Sandro S ^a   Gomes, Pedro P G ^a   Bacurau, Reury F P ^b   Ozaki, K Suzete ^a   Cenedeze, Marcos A ^a   Silva Filho, Alvaro P ^a,c   Câmara, Niels O S ^a,b   Araujo, Ronaldo C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

angiotensin I converting enzyme (ACE); B2 receptor; renal transplantation

Indexed keywords

BRADYKININ B2 RECEPTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT SURVIVAL; HUMAN; INDEL MUTATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; FEMALE; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, BRADYKININ B2;

EID: 84876513377     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0314     Document Type: Article

References (43)

1. Adarkwah, C.C., Gandjour, A., Akkerman, M., and Evers, S.M. (2011). Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands- a Markov model. PLoS One 6, e26139.
2. Akcay, A., Sezer, S., Ozdemir, F.N., Arat, Z., Atac, F.B., Verdi, H., Colak, T., and Haberal, M. (2004). Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. Transplantation 78, 892-898.
3. Alhenc-Gelas, F., Bouby, N., Richer, C., Potier, L., Roussel, R., and Marre, M. (2011). Kinins as therapeutic agents in cardiovascular and renal diseases. Curr. Pharm. Des. 17, 2654-2662.
4. Almeida, S.S., Barros, C.C., Moraes, M.R., Russo, F.J., Haro, A.S., Rosa, T.S., Alves, M.F., Pesquero, J.B., Carmona, A.K., Bacurau, R.F., et al. (2010). Plasma kallikrein and angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism. Neuropeptides 44, 139-143.
5. Almeida, S.S., Naffah-Mazzacoratti, M.G., Guimaraes, P.B., Wasinski, F., Pereira, F.E., Canzian, M., Centeno, R.S., Carrete, H., Yacubian, E.M., Carmona, A.K., et al. (2012). Carbamazepine inhibits angiotensin I-converting enzyme, linking it to the pathogenesis of temporal lobe epilepsy. Transl. Psychiatry 2, e93.
6. Alvim Rde, O., Santos, P.C., Nascimento, R.M., Coelho, G.L., Mill, J.G., Krieger, J.E., and Pereira, A.C. (2012). BDKRB2 + 9/-9 Polymorphism is associated with higher risk for diabetes mellitus in the Brazilian general population. Exp. Diabetes Res. 2012, 480251.
7. Braun, A., Kammerer, S., Maier, E., Bohme, E., and Roscher, A.A. (1996). Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykininassociated diseases. Immunopharmacology 33, 32-35.
8. Bryant, J.W. and Shariat-Madar, Z. (2009). Human plasma kallikreinkinin system: Physiological and biochemical parameters. Cardiovasc Hematol Agents Med. Chem. 7, 234-250.
9. Buleon, M., Mehrenberger, M., Pecher, C., Praddaude, F., Couture, R., Tack, I., and Girolami, J.P. (2007). [New perspectives for bradykinin in nephroprotection]. Med. Sci. (Paris) 23, 1141-1147.
10. Buleon, M., Allard, J., Jaafar, A., Praddaude, F., Dickson, Z., Ranera, M.T., Pecher, C., Girolami, J.P., and Tack, I. (2008). Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am. J. Physiol. Renal. Physiol. 294, F1249-1256.
11. Burrell, L.M., Burchill, L., Dean, R.G., Griggs, K., Patel, S.K., and Velkoska, E. (2012). Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp. Physiol. 97, 477-485.
12. Chawla, T., Sharma, D., and Singh, A. (2010). Role of the renin angiotensin system in diabetic nephropathy. World J. Diabetes 1, 141-145.
13. Danser, A.H. and Schunkert, H. (2000). Renin-angiotensin system gene polymorphisms: Potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 410, 303-316.
14. Fischer, M., Lieb, W., Marold, D., Berthold, M., Baessler, A., Lowel, H., Hense, H.W., Hengstenberg, C., Holmer, S., Schunkert, H., et al. (2004). Lack of association of a 9 bp insertion/deletion polymorphism within the bradykinin 2 receptor gene with myocardial infarction. Clin. Sci. (Lond.) 107, 505-511.
15. Francois, H., Jacquet, A., Beaudreuil, S., Seidowsky, A., Hebibi, H., Charpentier, B., and Durrbach, A. (2011). Emerging strategies to preserve renal function. J. Nephrol. 24, 133-141.
16. Gard, P.R. (2010). Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: A snapshot review. Int. J. Mol. Epidemiol. Genet. 1, 145-157.
17. Huang, X.R., Chen, W.Y., Truong, L.D., and Lan, H.Y. (2003). Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J. Am. Soc. Nephrol. 14, 1738-1747.
18. Jaspard, E., Wei, L., and Alhenc-Gelas, F. (1993). Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 268, 9496-9503.
19. Kakoki, M. and Smithies, O. (2009). The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int. 75, 1019-1030.
20. Kayashima, Y., Smithies, O., and Kakoki, M. (2012). The kallikreinkinin system and oxidative stress. Curr. Opin. Nephrol. Hypertens 21, 92-96.
21. Klahr, S., Levey, A.S., Beck, G.J., Caggiula, A.W., Hunsicker, L., Kusek, J.W., and Striker, G. (1994). The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330, 877-884.
22. Lee, Y.J., Jang, H.R., Kim, S.G., Chae, D.W., Do, J.Y., Lee, J.E., Huh, W., Kim, D.J., Oh, H.Y., and Kim, Y.G. (2011). Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms. Nephrology (Carlton) 16, 502-510.
23. Lewis, E.J., Hunsicker, L.G., Bain, R.P., and Rohde, R.D. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462.
24. Maric, C. (2008). Vasoactive hormones and the diabetic kidney. ScientificWorldJournal 8, 470-485.
25. Martinez-Rios, M.A., Pena-Duque, M.A., Fragoso, J.M., Delgadillo-Rodriguez, H., Perez-Hernandez, N., Miranda-Malpica, E., Rodriguez-Perez, J.M., Gonzalez-Quesada, C., and Vargas-Alarcon, G. (2008). No association found between the insertion/deletion of a 287-bp alu repeat sequence within intron 16 of the angiotensin-I-converting enzyme (ACE) gene in Mexican patients and binary restenosis after coronary stenting. Clin. Chim. Acta. 397, 65-67.
26. Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J.F., Motolese, M., Ponticelli, C., Ritz, E., and Zucchelli, P. (1996). Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945.
27. Mehta, R.L., Kellum, J.A., Shah, S.V., Molitoris, B.A., Ronco, C., Warnock, D.G., and Levin, A. (2007). Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care. 11, R31.
28. Mooyaart, A.L., Valk, E.J., van Es, L.A., Bruijn, J.A., de Heer, E., Freedman, B.I., Dekkers, O.M., and Baelde, H.J. (2011). Genetic associations in diabetic nephropathy: A meta-analysis. Diabetologia 54, 544-553.
29. Nakayama, Y., Nonoguchi, H., Kohda, Y., Inoue, H., Memetimin, H., Izumi, Y., and Tomita, K. (2009). Different mechanisms for the progression of CKD with ACE gene polymorphisms. Nephron. Clin. Pract. 111, c240-246.
30. Nicod, J., Richard, A., Frey, F.J., and Ferrari, P. (2002). Recipient RAS gene variants and renal allograft function. Transplantation 73, 960-965.
31. Putnam, K., Shoemaker, R., Yiannikouris, F., and Cassis, L.A. (2012). The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am. J. Physiol. Heart. Circ. Physiol. 302, H1219-1230.
32. Regoli, D. and Barabe, J. (1980). Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1-46.
33. Riad, A., Zhuo, J.L., Schultheiss, H.P., and Tschope, C. (2007). The role of the renal kallikrein-kinin system in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens 16, 22-26.
34. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., and Soubrier, F. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346.
35. Sabatini, R.A., Guimaraes, P.B., Fernandes, L., Reis, F.C., Bersanetti, P.A., Mori, M.A., Navarro, A., Hilzendeger, A.M., Santos, E.L., Andrade, M.C., et al. (2008). ACE activity is modulated by kinin B2 receptor. Hypertension 51, 689-695.
36. Santos, P.C., Krieger, J.E., and Pereira, A.C. (2012). Renin-angiotensin system, hypertension, and chronic kidney disease: Pharmacogenetic implications. J. Pharmacol. Sci. 120, 77-88.
37. Siekierka-Harreis, M., Kuhr, N., Willers, R., Ivens, K., Grabensee, B., Mondry, A., Loh, M.C., Rump, L.C., and Blume, C. (2009). Impact of genetic polymorphisms of the renin-angiotensin system and of non-genetic factors on kidney transplant function- a single-center experience. Clin. Transplant. 23, 606-615.
38. Su, S.L., Lu, K.C., Lin, Y.F., Hsu, Y.J., Lee, P.Y., Yang, H.Y., and Kao, S.Y. (2012). Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. J. Renin Angiotensin Aldosterone Syst. 13, 148-154.
39. Tang, S.C., Chan, L.Y., Leung, J.C., Cheng, A.S., Lan, H.Y., and Lai, K.N. (2011). Additive renoprotective effects of B2-kinin receptor blocker and PPAR-gamma agonist in uninephrectomized db/db mice. Lab. Invest.; A J. Tech. Methods and Pathology 91, 1351-1362.
40. Turner, J.M., Bauer, C., Abramowitz, M.K., Melamed, M.L., and Hostetter, T.H. (2012). Treatment of chronic kidney disease. Kidney Int. 81, 351-362.
41. Van Guilder, G.P., Pretorius, M., Luther, J.M., Byrd, J.B., Hill, K., Gainer, J.V., and Brown, N.J. (2008). Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 51, 454-459.
42. Vejakama, P., Thakkinstian, A., Lertrattananon, D., Ingsathit, A., Ngarmukos, C., and Attia, J. (2012). Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: A systematic review and network meta-analysis. Diabetologia 55, 566-578.
43. Vinson, G.P., Barker, S., and Puddefoot, J.R. (2012). The reninangiotensin system in the breast and breast cancer. Endocr. Relat. Cancer 19, R1-19.